Kiniksa Pharmaceuticals International, plc 8-K, filed Jan 14, 2026
Kiniksa Pharmaceuticals International, plc (KNSA)
About this 8-K
Kiniksa Pharmaceuticals International, plc filed this 8-K on January 14, 2026, reporting on events of January 10, 2026.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| | |||
(State or other jurisdiction of | | (Commission | | (I.R.S. Employer |
England,
(
(Address, zip code and telephone number, including area code of principal executive offices)
Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue
Lexington, MA, 02421
(781) 431-9100
(Address, zip code and telephone number, including area code of agent for service)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading | | Name of each exchange on which |
| | |||
| | | | (Nasdaq Global Select Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective January 10, 2026, the Board of Directors of Kiniksa Pharmaceuticals International, plc (the “Company”) appointed Ross Moat to the position of Chief Operating Officer and principal operating officer. Following the appointment, Mr. Moat will continue to oversee the Company’s commercial operations, in addition to functional operations under the Chief Operating Officer title. There were no changes to Mr. Moat’s compensation arrangements in connection with this appointment.
In addition, effective January 10, 2026, the Company’s Board of Directors appointed Eben Tessari to the position of Chief Strategy Officer. Mr. Tessari will continue to oversee the Company’s strategic, business development and technical operations, in addition to responsibility for the Company’s artificial intelligence initiatives. There were no changes to Mr. Tessari’s compensation arrangements in connection with this appointment.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC | |
| | |
Date: January 14, 2026 | By: | /s/ Douglas Barry |
| | Douglas Barry |
| | Senior Vice President, Chief Legal Officer |